

29 May 2025

Physiomics plc
("Physiomics" or the "Company")

Physiomics Awarded Contract Extension

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a sizeable contract extension award with an existing large pharma client.

The project builds upon the contract award announced on 13 June 2024, where the Company's proprietary Virtual Tumour platform has been used to model the client's targeted oncology agents in combination with other modalities so to help inform dose and scheduling decisions. This contract extension allows the continuation of this work and further supports the client's expansion into new oncology indications. The project is valued at £143,780 and is projected to complete over the next six months, with the majority of the contract's value being recognised in the financial year ending 30 June 2026.

Dr Peter Sargent, CEO of Physiomics, commented:

"We are thrilled to have been awarded this sizeable contract extension. The award is testament to the continuation of our deep relationship with this large pharma client and the positive impact we have on their oncology portfolio. It also reflects the power and utility of our Virtual Tumour platform in supporting novel oncology therapies, especially in modelling therapies used in combination with other modalities."

For more information about Physiomics and its services, please visit www.physiomics.co.uk.

Enquiries:

Physiomics plc
Dr Peter Sargent, CEO
+44 (0)1235 841575

Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics

team has informed the development of over 100 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

CNTUWRBRVWUVUAR